Adam Asch to Rituximab
This is a "connection" page, showing publications Adam Asch has written about Rituximab.
Connection Strength
0.096
-
Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial. Lancet Oncol. 2022 08; 23(8):1021-1030.
Score: 0.050
-
A phase II trial of bendamustine in combination with rituximab in older patients with previously untreated diffuse large B-cell lymphoma. Br J Haematol. 2016 Oct; 175(2):281-289.
Score: 0.033
-
Rituximab in the treatment of acquired factor VIII inhibitors. Blood. 2002 Nov 01; 100(9):3426-8.
Score: 0.013